Is Angiotensin-(1-7) legal in Canada?

The counter-regulatory arm of the renin-angiotensin system, made from angiotensin II by ACE2. It has been given to people in cancer, transplant and COVID-19 trials; the phase 1 cancer study recorded a stroke and a reversible cranial neuropathy as dose-limiting toxicities, and most of the company programme was terminated or withdrawn.

Angiotensin-(1-7) is a 7 amino acid peptide, sequence DRVYIHP, cut from angiotensin II by ACE2. It signals through the Mas receptor and opposes the vasoconstrictive, pro-fibrotic AT1 arm of the same system.

Mechanism: In humans, ACE2 converts angiotensin II to angiotensin-(1-7), which binds the Mas receptor (gene MAS1). Established human pharmacology is limited: the phase 1 study measured plasma concentrations and a fall in placental growth factor in the patients who had clinical benefit, and the phase 2 study confirmed a rise in plasma angiotensin-(1-7) 4 hours after injection but did not reproduce the biomarker change.

Regulatory history: Not approved by the FDA for any indication. Developed clinically as TXA127; no marketing application has been approved and no angiotensin-(1-7) product appeared in the 11 September 2026 Drugs@FDA checks.

Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.

The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for Angiotensin-(1-7) at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.